Bluexy
sociopath
Registered: Feb 2004
Location: Centrally isolated
Posts: 280 |
quote: Originally posted by ignatz mouse
translation of this translation: [sorry, we don't speak academese.]
The report in Blood was funded (in part) by the National Institutes of Health (NIH) through a competitve grant that must be renewed. It is highly likely that Jordan's grant is approaching renewal and they are looking for a little high-profile grease. This is typically accomplished by going to the PR office and telling them about some new result, which they subsequently spin to media outlets. It is much easier to give a reporter a pre-written snipet than to have them create one independently.
Why do I even mention this, or consider it (other than the fact that it happens daily)? (A) If you had a magic bullet for LSC, or any potential drug with such amazing specificity, you visit technology transfer people. You do not publish it in Blood, you wait for protection and send it to Nature. (B) The active compound is one derivative of a broad class of lactones that exhibit all types of nonspecific biological activity - from breast cancer lines to bone growth. (C) It is only sparingly soluble in water, although some "private communication" is mentioned regarding a more soluble derivative, but no activity reports are given. It is possible these are also active, and disclosures or patents are being filed, but even in that case you do not anounce it to Merck, Pfizer, or any drug company reading your work.
Dollars to doughnuts, this is grant related. IMHO.
Edit - On a personal level, I hope they ultimately find a "magic bullet."
Last edited by Bluexy on 02-24-2005 at 08:34 PM
Report this post to a moderator |
IP: Logged
|